A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice

Jan Sedlacik, Adrianne Myers, Ralf B. Loeffler, Regan Williams, Andrew M. Davidoff, Claudia M. Hillenbrand

Research output: Contribution to journalArticle

Abstract

Purpose: To develop a reproducible small-animal dynamic contrast-enhanced (DCE) MRI set-up for mice through which volumes <100 μL can be accurately and safely injected and to test this set-up by means of DCE measurements in resting muscle and tumor tissue. Materials and Methods: The contrast agent (CA) injection system comprised 2 MR-compatible syringe pumps placed 50 cm from the 7T magnet bore where the fringe field is approximately 40 mT. Microbore tubing and T-connector, close to the injection site, minimized dead volume (<10 μL). For DCE-MRI measurements in 8 CB-17 SCID mice with 1500-2500 mm 3 large orthotopic neuroblastoma, a bolus of 10-fold-diluted Gd-DTPA CA solution (0.1 mmol/kg) was delivered (5 μL/s), followed by a 50-μL saline flush. Retro-orbital injections were given instead of tail vein injections, because the peripheral vasculature was reduced because of large tumor burden. Results: The CA injection was successful in 19 of 24 experiments. Optical assessment showed minimal dispersion of ink-colored CA bolus. Mean (±SD) pharmacokinetic parameters retrieved from DCE-MRI examinations in resting muscle (Ktrans = 0.038 ± 0.025 min-1, kep = 0.66 ± 0.48 min-1, ve = 0.060 ± 0.014, vp = 0.033 ± 0.021) and tumor (K trans = 0.082 ± 0.071 min-1, kep = 0.82 ± 0.80 min-1, ve = 0.121 ± 0.075, v p = 0.093 ± 0.051) agreed with those reported previously. Conclusion: We successfully designed and implemented a DCE-MRI set-up system with short injection lines and low dead volume. The system can be used at any field strength with the syringe pumps placed at a sufficiently low fringe field (<40 mT).

Original languageEnglish (US)
Pages (from-to)746-751
Number of pages6
JournalJournal of Magnetic Resonance Imaging
Volume37
Issue number3
DOIs
StatePublished - Mar 1 2013

Fingerprint

Contrast Media
Injections
Syringes
Muscles
Gadolinium DTPA
Ink
SCID Mice
Magnets
Tumor Burden
Neuroblastoma
Tail
Veins
Neoplasms
Pharmacokinetics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice. / Sedlacik, Jan; Myers, Adrianne; Loeffler, Ralf B.; Williams, Regan; Davidoff, Andrew M.; Hillenbrand, Claudia M.

In: Journal of Magnetic Resonance Imaging, Vol. 37, No. 3, 01.03.2013, p. 746-751.

Research output: Contribution to journalArticle

Sedlacik, Jan ; Myers, Adrianne ; Loeffler, Ralf B. ; Williams, Regan ; Davidoff, Andrew M. ; Hillenbrand, Claudia M. / A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice. In: Journal of Magnetic Resonance Imaging. 2013 ; Vol. 37, No. 3. pp. 746-751.
@article{d2e6af03c97b448e8f575a5f6748b277,
title = "A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice",
abstract = "Purpose: To develop a reproducible small-animal dynamic contrast-enhanced (DCE) MRI set-up for mice through which volumes <100 μL can be accurately and safely injected and to test this set-up by means of DCE measurements in resting muscle and tumor tissue. Materials and Methods: The contrast agent (CA) injection system comprised 2 MR-compatible syringe pumps placed 50 cm from the 7T magnet bore where the fringe field is approximately 40 mT. Microbore tubing and T-connector, close to the injection site, minimized dead volume (<10 μL). For DCE-MRI measurements in 8 CB-17 SCID mice with 1500-2500 mm 3 large orthotopic neuroblastoma, a bolus of 10-fold-diluted Gd-DTPA CA solution (0.1 mmol/kg) was delivered (5 μL/s), followed by a 50-μL saline flush. Retro-orbital injections were given instead of tail vein injections, because the peripheral vasculature was reduced because of large tumor burden. Results: The CA injection was successful in 19 of 24 experiments. Optical assessment showed minimal dispersion of ink-colored CA bolus. Mean (±SD) pharmacokinetic parameters retrieved from DCE-MRI examinations in resting muscle (Ktrans = 0.038 ± 0.025 min-1, kep = 0.66 ± 0.48 min-1, ve = 0.060 ± 0.014, vp = 0.033 ± 0.021) and tumor (K trans = 0.082 ± 0.071 min-1, kep = 0.82 ± 0.80 min-1, ve = 0.121 ± 0.075, v p = 0.093 ± 0.051) agreed with those reported previously. Conclusion: We successfully designed and implemented a DCE-MRI set-up system with short injection lines and low dead volume. The system can be used at any field strength with the syringe pumps placed at a sufficiently low fringe field (<40 mT).",
author = "Jan Sedlacik and Adrianne Myers and Loeffler, {Ralf B.} and Regan Williams and Davidoff, {Andrew M.} and Hillenbrand, {Claudia M.}",
year = "2013",
month = "3",
day = "1",
doi = "10.1002/jmri.23810",
language = "English (US)",
volume = "37",
pages = "746--751",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice

AU - Sedlacik, Jan

AU - Myers, Adrianne

AU - Loeffler, Ralf B.

AU - Williams, Regan

AU - Davidoff, Andrew M.

AU - Hillenbrand, Claudia M.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Purpose: To develop a reproducible small-animal dynamic contrast-enhanced (DCE) MRI set-up for mice through which volumes <100 μL can be accurately and safely injected and to test this set-up by means of DCE measurements in resting muscle and tumor tissue. Materials and Methods: The contrast agent (CA) injection system comprised 2 MR-compatible syringe pumps placed 50 cm from the 7T magnet bore where the fringe field is approximately 40 mT. Microbore tubing and T-connector, close to the injection site, minimized dead volume (<10 μL). For DCE-MRI measurements in 8 CB-17 SCID mice with 1500-2500 mm 3 large orthotopic neuroblastoma, a bolus of 10-fold-diluted Gd-DTPA CA solution (0.1 mmol/kg) was delivered (5 μL/s), followed by a 50-μL saline flush. Retro-orbital injections were given instead of tail vein injections, because the peripheral vasculature was reduced because of large tumor burden. Results: The CA injection was successful in 19 of 24 experiments. Optical assessment showed minimal dispersion of ink-colored CA bolus. Mean (±SD) pharmacokinetic parameters retrieved from DCE-MRI examinations in resting muscle (Ktrans = 0.038 ± 0.025 min-1, kep = 0.66 ± 0.48 min-1, ve = 0.060 ± 0.014, vp = 0.033 ± 0.021) and tumor (K trans = 0.082 ± 0.071 min-1, kep = 0.82 ± 0.80 min-1, ve = 0.121 ± 0.075, v p = 0.093 ± 0.051) agreed with those reported previously. Conclusion: We successfully designed and implemented a DCE-MRI set-up system with short injection lines and low dead volume. The system can be used at any field strength with the syringe pumps placed at a sufficiently low fringe field (<40 mT).

AB - Purpose: To develop a reproducible small-animal dynamic contrast-enhanced (DCE) MRI set-up for mice through which volumes <100 μL can be accurately and safely injected and to test this set-up by means of DCE measurements in resting muscle and tumor tissue. Materials and Methods: The contrast agent (CA) injection system comprised 2 MR-compatible syringe pumps placed 50 cm from the 7T magnet bore where the fringe field is approximately 40 mT. Microbore tubing and T-connector, close to the injection site, minimized dead volume (<10 μL). For DCE-MRI measurements in 8 CB-17 SCID mice with 1500-2500 mm 3 large orthotopic neuroblastoma, a bolus of 10-fold-diluted Gd-DTPA CA solution (0.1 mmol/kg) was delivered (5 μL/s), followed by a 50-μL saline flush. Retro-orbital injections were given instead of tail vein injections, because the peripheral vasculature was reduced because of large tumor burden. Results: The CA injection was successful in 19 of 24 experiments. Optical assessment showed minimal dispersion of ink-colored CA bolus. Mean (±SD) pharmacokinetic parameters retrieved from DCE-MRI examinations in resting muscle (Ktrans = 0.038 ± 0.025 min-1, kep = 0.66 ± 0.48 min-1, ve = 0.060 ± 0.014, vp = 0.033 ± 0.021) and tumor (K trans = 0.082 ± 0.071 min-1, kep = 0.82 ± 0.80 min-1, ve = 0.121 ± 0.075, v p = 0.093 ± 0.051) agreed with those reported previously. Conclusion: We successfully designed and implemented a DCE-MRI set-up system with short injection lines and low dead volume. The system can be used at any field strength with the syringe pumps placed at a sufficiently low fringe field (<40 mT).

UR - http://www.scopus.com/inward/record.url?scp=84874245343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874245343&partnerID=8YFLogxK

U2 - 10.1002/jmri.23810

DO - 10.1002/jmri.23810

M3 - Article

VL - 37

SP - 746

EP - 751

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 3

ER -